With advances in early detection and cancer treatment over the past decade, such as immunotherapy, we see the accelerated drops in lung cancer mortality as well as in melanoma, and long-term drops in death rates in colorectal, breast, and prostate cancer. While survival rates for other cancers have increased in the last 40 years, only 7% - 10% of people with pancreatic cancer currently survive for 5 years or longer. This type of cancer with the highest mortality rate of all major cancers is often detected late, spreads rapidly, and has a poor prognosis. A lack of ways to diagnose this cancer early and the largely asymptomatic nature of the disease means that most people are diagnosed at an advanced stage when treatments such as chemotherapy are not as effective.

To meet the needs of pancreatic cancer researchers and support the pancreatic cancer drug development, TargetMol collects 2238 compounds related to pancreatic cancer, targeting KRas, MEK, ERK, RAF, PI3K, HER2, EGFR, JAK/STAT, IGF-1R, VEGF, TGFβ, etc.